GlassScriptPhysician profile
Swati Jai Parekh
NPI 1427087725
$40,550.60
in general payments reported to CMS, 2019-2025
41 companies · $7,690 in 2025
The $7,690 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,375 · 2020: $1,222 · 2021: $3,145 · 2022: $4,705 · 2023: $8,702 · 2024: $13K · 2025: $7,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $14K · Travel and Lodging: $93.14 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,664.57 |
| Consulting Fee | $14,327.50 |
| Travel and Lodging | $93.14 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $16,657.87 | 2022-2025 | Envista Aspire Iol, Miebo, Xiidra |
| Sight Sciences, INC. | $3,115.73 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| New World Medical,INC. | $2,564.71 | 2019-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Abbvie INC. | $2,346.11 | 2022-2025 | |
| Glaukos Corporation | $2,237.83 | 2019-2025 | Idose, Iaccess Precision Blade, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Johnson & Johnson Surgical Vision, INC. | $1,888.84 | 2020-2025 | Lipiflow System Activator (Disposable), Tecnis Iol, One Series Ultra |
| Allergan, INC. | $1,688.43 | 2019-2022 | |
| Alcon Vision LLC | $1,336.81 | 2021-2025 | Clareon, Tryptyr, Rocklatan |
| Eyepoint US, INC. | $1,329.70 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $698.92 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $532.11 | 2019-2021 | |
| Ocular Therapeutix, INC. | $530.29 | 2020-2024 | Dextenza |
| Oyster Point Pharma, INC. | $452.92 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $443.95 | 2021-2025 | Oxervate |
| Rxsight INC | $442.58 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$450,081.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Parekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.